Markers of oxidative damage in chronic heart failure: Role in disease progression

Redox Report

Volumn 13, Issue 3, 2008, Pages 109-116

  Radovanovic, Slavica ^a   Krotin, Mirjana ^a   Simic, Dragan V ^a   Mimic Oka, Jasmina ^b   Savic Radojevic, Ana ^b   Pljesa Ercegovac, Marija ^b   Matic, Marija ^b   Ninkovic, Nebojsa ^a   Ivanovic, Branislava ^a   Simic, Tatjana ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

8 epi PGF2 ; Chronic heart failure; Oxidative damage

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; BIOLOGICAL MARKER; CREATININE; ISOPROSTANE; MALONALDEHYDE; THIOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; MALE; OXIDATIVE STRESS; PATHOGENESIS; PATIENT CODING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFECT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; CHRONIC DISEASE; DINOPROST; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; ISOPROSTANES; LIPIDS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; VENTRICULAR REMODELING;

EID: 48749103531     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/135100008X259204     Document Type: Article

References (24)

1. Tarone G, Lembo G. Molecular interplay between mechanical and humoral signaling in cardiac hypertrophy. Trends Mol Med 2003; 9: 376-82.
2. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic failure in humans. Eur Heart J 1993; 14: 1493-8.
3. 2α. Eur J Heart Fail 2005; 7: 167-72.
4. Polidori MC, Savino K, Alunni G et al. Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: relationship to disease severity. Free Radic Biol Med 2002; 32: 148-52.
5. 2α in pericardial fluid of patients with heart failure. Circulation 1998; 97: 1536-9.
6. Cracowski JL, Tremel F, Marpeau C et al. Increased formation of F(2) isoprostanes in patients with severe heart failure. Heart 2000; 84: 439-40.
7. Takano H, Hasegawa H, Nagai T, Komuro I. Implication of cardiac remodeling in heart failure: Mechanisms and therapeutic strategies. Intern Med 2003; 42: 465-9.
8. Mehrabi MR, Ekmekcioglu C, Tatzber F, Oguogho A, Ullrich R, Morgan A. The isoprostane, 8-epi-PGF2 alpha, is accumulated in coronary arteries isolated from patients with coronary heart disease. Cardiovasc Res 1999; 43: 492-9.
9. 2+-ATPase. Arch Biochem Biophys 1986; 246: 589-601.
10. Kupchak P, Wu AH, Ghani F, Newby LK, Ohman EM, Christenson RH. Influence of imprecision on ROC curve analysis for cardiac markers. Clin Chem 2006; 52: 752-3.
11. Halliwell B. Reactive oxygen species in living systems. Source, biochemistry and role. Am J Med 1991; 9: 114-22.
12. Miao-Lin Hu. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994; 233: 380-5.
13. Jocelyn PC. Spectrophotometric assay of thiols. Methods Enzymol 1987; 143: 44-67.
14. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviramn M. Reduced susceptibility of low-density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997; 128: 11-8.
15. Castro P, Vukasovic JL, Chiong M et al. Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. Eur J Heart Fail 2005; 7: 1033-9
16. Singal PK, Khaper N, Farahmand F, Bello-Klein A. Oxidative stress in congestive heart failure. Curr Cardiol Rep 2000; 2: 206-11.
17. Willenbrock R, Philipp S, Mitrovic V, Dietz R. Neurohumoral blockade in CHF management. J Renin Angiotensin Aldosterone Syst 2000; 1 (Suppl 1): 24-30.
18. Kromer BM, Tippins JR. Coronary artery constriction by the isoprostane 8-epi prostaglandin F2 alpha. Br J Pharmacol 1996; 119: 1276-80.
19. Takahashi K, Nammour TM, Fukunaga M et al. Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. J Clin Invest 1992; 90: 136-41.
20. Hoffman SW, Moore S, Ellis EF. Isoprostanes: Free radical-generated prostaglandins with constrictor effects on cerebral arterioles. Stroke 1997; 28: 844-9.
21. Truog WE, Norberg M, Thibeault DW. Effects of 8-epi-prostaglandin F2 alpha and U46,619 on pulmonary hemodynamics in piglets. Biol Neonat 1997; 71: 306-16.
22. Takano H, Zou Y, Hasegawa H, Akazawa H, Nagai T, Komuro I. Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxid Redox Signal 2003; 5: 789-94.
23. Dhalla NS, Dent MR, Tappia PS, Sethi R, Barta J, Goyal RK. Subcellular remodeling as a viable target for the treatment of congestive heart failure. J Cardiovasc Pharmacol Ther 2006; 11: 31-45.
24. Tsutsui H. Novel pathophysiological insight and treatment strategies for heart failure-lessons from mice and patients. Circ J 2004; 68: 1095-103.